Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Crow's feet

8 clinical trials

6 products

Clinical trial
A Multicenter, Long-term, Open-label Study to Evaluate the Safety of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines and Lateral Canthal Lines
Status: Completed, Estimated PCD: 2023-02-16
Product
MT10109L
Clinical trial
Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Product
Vehicle
Product
Botulinum Toxin Type A
Product
DaxibotulinumtoxinA
Clinical trial
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines
Status: Completed, Estimated PCD: 2020-03-05
Product
Placebo
Clinical trial
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy, Safety, and Duration of Benefit of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
Status: Completed, Estimated PCD: 2020-04-23
Product
Botulinum toxin
Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines
Status: Completed, Estimated PCD: 2020-02-27
Clinical trial
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
Status: Completed, Estimated PCD: 2020-03-05
Clinical trial
A Multicenter, Open-Label Study to Evaluate the Safety of QM1114-DP for the Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
Status: Completed, Estimated PCD: 2021-04-12
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines
Status: Completed, Estimated PCD: 2020-09-25